NEW YORK (GenomeWeb) – UK-based Proteome Sciences is moving towards a more focused business model based on the company's pharmaceutical services offerings, GenomeWeb has learned.

In an interview last week, Jeremy Haigh, who recently appointed Proteome Sciences' CEO, noted that while the company has considerable expertise in a variety of proteomics workflows and a collection of potentially valuable intellectual property, it has struggled to translate these assets into consistent profits.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.